Literature DB >> 30359164

Influence of concentration and preparation of platelet rich fibrin on human bone marrow mononuclear cells (in vitro).

René Verboket1, Carlos Herrera-Vizcaíno2, Kirsten Thorwart1, Patrick Booms2, Marlene Bellen1, Sarah Al-Maawi2, Robert Sader2, Ingo Marzi1, Dirk Henrich1, Shahram Ghanaati2.   

Abstract

Large bone defects have always been a big challenge. The use of bone marrow mononuclear cells (BMCs) combined with an osteoconductive scaffold has been proved a good alternative for the treatment of large bone defects. Another autologous source for tissue engineering is platelet rich fibrin (PRF). PRF is a blood concentrate system obtained through a one-step centrifugation. The generated 3D matrix of the PRF clot serves as a reservoir of growth factors. Those growth factors might support the regenerative response of BMC, and therefore the effect of PRF, centrifuged with either high medium (208 g) or low (60 g) relative centrifugation force (RCF) on BMCs was evaluated in vitro in the present study. The two PRF matrices obtained were initially characterized and compared to human serum. Significantly increased concentrations of insulin-like growth factor (IGF), soluble intercellular adhesion molecule-1 (sICAM1) and transforming growth factor (TGF)-β were found in PRF compared to human serum whereas VEGF concentration was not significantly altered. A dose-response study revealed no further activation of BMC's metabolic activity, if concentration of both PRF matrices exceeded 10% (v/v). Effect of both PRF preparations [10%] on BMC was analyzed after 2, 7, and 14 days in comparison to human serum [10%]. Metabolic activity of BMC increased significantly in all groups on day 14. Furthermore, gene expression of matrix metalloproteinases (MMP)-2, -7, and -9 was significantly stimulated in BMC cultivated with the respective PRF matrices compared to human serum. Apoptotic activity of BMC incubated with PRF was not altered compared to BMC cultivated with serum. In conclusion, PRF could be used as a growth factor delivery system of autologous or allogeneic source with the capability of stimulating cells such as BMC.

Entities:  

Keywords:   BMC, PRF, tissue engineering, bone healing, LSCC

Mesh:

Year:  2018        PMID: 30359164     DOI: 10.1080/09537104.2018.1530346

Source DB:  PubMed          Journal:  Platelets        ISSN: 0953-7104            Impact factor:   3.862


  3 in total

1.  Allogeneic Fibrin Clot for Odontogenic/Cementogenic Differentiation of Human Dental Mesenchymal Stem Cells.

Authors:  Hua-Lian Cao; Jong Hoon Chung; Pill-Hoon Choung
Journal:  Tissue Eng Regen Med       Date:  2020-06-26       Impact factor: 4.169

2.  Effect of platelet-rich fibrin on cell proliferation, migration, differentiation, inflammation, and osteoclastogenesis: a systematic review of in vitro studies.

Authors:  Franz-Josef Strauss; Jila Nasirzade; Zahra Kargarpoor; Alexandra Stähli; Reinhard Gruber
Journal:  Clin Oral Investig       Date:  2019-12-26       Impact factor: 3.606

3.  Determination of the effective dose of bone marrow mononuclear cell therapy for bone healing in vivo.

Authors:  Maren Janko; Sabrina Pöllinger; Alexander Schaible; Marlene Bellen; Katrin Schröder; Myriam Heilani; Charlotte Fremdling; Ingo Marzi; Christoph Nau; Dirk Henrich; René D Verboket
Journal:  Eur J Trauma Emerg Surg       Date:  2020-02-28       Impact factor: 3.693

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.